Urogen Pharma (NASDAQ:URGN) Shares Gap Down – Time to Sell?

Urogen Pharma (NASDAQ:URGN – Get Free Report) gapped down before the market opened on Monday. The stock had previously closed at $26.18, but opened at $24.00. Urogen Pharma shares last traded at $25.5580, with a volume of 311,241 shares traded.

Analyst Ratings Changes

Several equities analysts recently issued reports on URGN shares. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Urogen Pharma in a research note on Monday, October 19th. Guggenheim dropped their price target on shares of Urogen Pharma from $58.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, November 5th. TD Cowen raised their price target on shares of Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $56.00 price objective on shares of Urogen Pharma in a report on Thursday, September 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Thursday, October 15th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Urogen Pharma has a consensus rating of “Moderate Buy” and an average price target of $53.38.

Check Out Our Latest Stock Analysis on Urogen Pharma

Urogen Pharma Trading Up 6.3%

The business has a 50-day simple moving average of $36.40 and a 200-day simple moving average of $31.75.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million for the quarter, compared to the consensus estimate of $89.92 million. As a group, equities analysts forecast that Urogen Pharma will post -0.36 EPS for the current fiscal year.

Insider Transactions at Urogen Pharma

In other news, CFO Chris Degnan sold 2,202 shares of the stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $36.69, for a total value of $80,791.38. Following the completion of the sale, the chief financial officer directly owned 4,561 shares in the company, valued at $167,343.09. This represents a 32.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Schoenberg sold 871 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total transaction of $37,383.32. Following the completion of the transaction, the insider directly owned 59,882 shares in the company, valued at approximately $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 65,269 shares of company stock valued at $3,037,646 over the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Urogen Pharma

A number of hedge funds have recently bought and sold shares of URGN. BlackRock Inc. purchased a new stake in shares of Urogen Pharma in the second quarter valued at about $117,814,000. Jefferies Financial Group Inc. acquired a new stake in Urogen Pharma during the second quarter worth about $80,947,000. Opaleye Management Inc. increased its position in Urogen Pharma by 0.7% during the second quarter. Opaleye Management Inc. now owns 1,439,996 shares of the company’s stock worth $52,992,000 after purchasing an additional 9,996 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Urogen Pharma by 3.5% during the third quarter. Goldman Sachs Group Inc. now owns 848,342 shares of the company’s stock worth $34,468,000 after purchasing an additional 28,508 shares during the period. Finally, Bank of America Corp DE purchased a new position in Urogen Pharma during the second quarter worth about $17,506,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

(Get Free Report)

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.

Further Reading

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.